Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Hypertension Research
  • View all journals
  • Search
  • Log in
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. hypertension research
  3. original article
  4. article
Alteration of Serum Soluble Endoglin Levels after the Onset of Preeclampsia Is More Pronounced in Women with Early-Onset
Download PDF
Download PDF
  • Original Article
  • Published: 01 August 2008

Alteration of Serum Soluble Endoglin Levels after the Onset of Preeclampsia Is More Pronounced in Women with Early-Onset

  • Chikako Hirashima1 na1,
  • Akihide Ohkuchi1 na1,
  • Shigeki Matsubara1,
  • Hirotada Suzuki1,
  • Kayo Takahashi1,
  • Rie Usui1 &
  • …
  • Mitsuaki Suzuki1 

Hypertension Research volume 31, pages 1541–1548 (2008)Cite this article

  • 1338 Accesses

  • Metrics details

Abstract

It has been established that serum soluble endoglin (sEng) increases in women with preeclampsia. However, sEng levels have not been evaluated using a normal reference value specific to each gestational age. First, we established the normal reference value for sEng using 85 pregnant controls without preeclampsia, from whom serum samples were collected three times at 20–23, 27–30, and 36–38 weeks of gestation. Second, we evaluated the serum sEng levels after the onset of preeclampsia in 56 preeclamptic patients. In three women (3.5%) with normal pregnancies, sustained high sEng levels (>15 ng/mL) were observed. We calculated the reference value for sEng using the remaining 82 normal controls. The log10sEng was almost normally distributed at each gestational week during 20–38 weeks, and the mean log10sEng was represented as a quadratic curve of gestational week. The SD of log10sEng was represented as a linear equation of gestational week. The mean log10sEng significantly and gradually increased from 20–23 weeks to 27–30 weeks of gestation and then rapidly increased at 36–38 weeks of gestation. Ninety-three percent of preeclamptic women showed sEng≥95th percentile of the reference value. The log10sEng levels and the SD score (SDS) of log10sEng in women with early-onset preeclampsia (onset<32 weeks of gestation) were significantly higher than those in women with late-onset preeclampsia (onset≥32 weeks of gestation) (1.97±0.23 vs. 1.78±0.28, 9.94±2.61 vs. 4.47±2.06, respectively). In conclusion, alteration of serum sEng levels after the onset of preeclampsia was more pronounced in women with early-onset preeclampsia compared to those with late onset.

Similar content being viewed by others

Maternal angiogenic factor disruptions prior to clinical diagnosis of preeclampsia: insights from the REVAMP study

Article 04 July 2024

Routinely collected antenatal data for longitudinal prediction of preeclampsia in nulliparous women: a population-based study

Article Open access 09 September 2021

Thrombin cleaves membrane-bound endoglin potentially contributing to the heterogeneity of circulating endoglin in preeclampsia

Article Open access 26 February 2025

Article PDF

References

  1. Ohkuchi A, Iwasaki R, Suzuki H, et al: Normal and high-normal blood pressures, but not body mass index, are risk factors for the subsequent occurrence of both preeclampsia and gestational hypertension: a retrospective cohort study. Hypertens Res 2006; 29: 161–167.

    Article  Google Scholar 

  2. Nagaya K, Fetters MD, Ishikawa M, et al: Causes of maternal mortality in Japan. JAMA 2000; 283: 2661–2667.

    Article  CAS  Google Scholar 

  3. Hecher K, Campbell S, Doyle P, Harrington K, Nicolaides K : Assessment of fetal compromise by Doppler ultrasound investigation of the fetal circulation. Arterial, intracardiac, and venous blood flow velocity studies. Circulation 1995; 91: 129–138.

    Article  CAS  Google Scholar 

  4. Maruyama A, Nakayama T, Sato N, Mizutani Y, Furuya K, Yamamoto T : Association study using single nucleotide polymorphisms in the estrogen receptor beta (ESR2) gene for preeclampsia. Hypertens Res 2004; 27: 903–909.

    Article  CAS  Google Scholar 

  5. Chappell S, Morgan L : Searching for genetic clues to the causes of pre-eclampsia. Clin Sci (Lond) 2006; 110: 443–458.

    Article  CAS  Google Scholar 

  6. Molvarec A, Vér A, Fekete A, et al: Association between estrogen receptor α (ESR1) gene polymorphisms and severe preeclampsia. Hypertens Res 2007; 30: 205–211.

    Article  CAS  Google Scholar 

  7. Levine RJ, Maynard SE, Qian C, et al: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672–683.

    Article  CAS  Google Scholar 

  8. Maynard SE, Min JY, Merchan J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sF1t1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649–658.

    Article  CAS  Google Scholar 

  9. Ohkuchi A, Hirashima C, Matsubara S, et al: Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 2007; 30: 151–159.

    Article  CAS  Google Scholar 

  10. Hirashima C, Ohkuchi A, Arai F, et al: Establishing reference values for both total soluble fms-like tyrosine kinase 1 and free placental growth factor in pregnant women. Hypertens Res 2005; 28: 727–732.

    Article  CAS  Google Scholar 

  11. Chaiworapongsa T, Romero R, Kim YM, et al: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of preeclampsia. J Matern Fetal Neonatal Med 2005; 17: 3–18.

    Article  CAS  Google Scholar 

  12. Venkatesha S, Toporsian M, Lam C, et al: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642–649.

    Article  CAS  Google Scholar 

  13. Levine RJ, Lam C, Qian C, et al: CPEP Study Group: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992–1005.

    Article  CAS  Google Scholar 

  14. Lebrin F, Deckers M, Bertolino P, Ten Dijke P : TGF-beta receptor function in the endothelium. Cardiovasc Res 2005; 65: 599–608.

    Article  CAS  Google Scholar 

  15. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y : Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab 2007; 92: 2672–2679.

    Article  CAS  Google Scholar 

  16. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH : Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007; 197: 28.e 1–28.e6.

    Article  Google Scholar 

  17. Staff AC, Braekke K, Johnsen GM, Karumanchi SA, Harsem NK : Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol 2007; 197: 176.e1–176.e6.

    Article  Google Scholar 

  18. Sato K : A proposal for a new definition and classification of “Pregnancy Induced Hypertension (PIH)” (2004), in Japan Society for the Study of Toxemia of Pregnancy (ed): Historical Perspective of Study of Pregnancy-Induced Hypertension in Japan. Tokyo, Medical View Co, 2005, 54–87.

  19. Ogawa Y, Iwamura T, Kuriya N, et al: Birth size standards by gestational age for Japanese neonates. Acta Neonatologica Japonica 1998; 34: 624–632.

    Google Scholar 

  20. Rana S, Karumanchi SA, Levine RJ, et al: Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007; 50: 137–142.

    Article  CAS  Google Scholar 

  21. Robinson CJ, Johnson DD : Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007; 197: 174.e1–174.e5.

    Article  Google Scholar 

  22. Lopez-Novoa JM : Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant 2007; 22: 712–714.

    Article  CAS  Google Scholar 

  23. Lowe DT : Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000; 4: 441–458.

    Article  CAS  Google Scholar 

  24. Cudmore M, Ahmad S, Al-Ani B, et al: Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789–1797.

    Article  CAS  Google Scholar 

  25. Ahmed A, Rahman M, Zhang X, et al: Induction of placental heme oxygenase-1 is protective against TNFalpha-induced cytotoxicity and promotes vessel relaxation. Mol Med 2000; 6: 391–409.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes
  1. Chikako Hirashima and Akihide Ohkuchi: These authors contributed equally to this work

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Jichi Medical University School of Medicine, Shimotsuke, Japan

    Chikako Hirashima, Akihide Ohkuchi, Shigeki Matsubara, Hirotada Suzuki, Kayo Takahashi, Rie Usui & Mitsuaki Suzuki

Authors
  1. Chikako Hirashima
    View author publications

    Search author on:PubMed Google Scholar

  2. Akihide Ohkuchi
    View author publications

    Search author on:PubMed Google Scholar

  3. Shigeki Matsubara
    View author publications

    Search author on:PubMed Google Scholar

  4. Hirotada Suzuki
    View author publications

    Search author on:PubMed Google Scholar

  5. Kayo Takahashi
    View author publications

    Search author on:PubMed Google Scholar

  6. Rie Usui
    View author publications

    Search author on:PubMed Google Scholar

  7. Mitsuaki Suzuki
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Akihide Ohkuchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirashima, C., Ohkuchi, A., Matsubara, S. et al. Alteration of Serum Soluble Endoglin Levels after the Onset of Preeclampsia Is More Pronounced in Women with Early-Onset. Hypertens Res 31, 1541–1548 (2008). https://doi.org/10.1291/hypres.31.1541

Download citation

  • Received: 12 January 2008

  • Accepted: 27 April 2008

  • Issue date: 01 August 2008

  • DOI: https://doi.org/10.1291/hypres.31.1541

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • soluble endoglin
  • early-onset preeclampsia
  • late-onset preeclampsia
  • pregnancy

This article is cited by

  • The role of endoglin and its soluble form in pathogenesis of preeclampsia

    • Georgia Margioula-Siarkou
    • Chrysoula Margioula-Siarkou
    • Georgios Mavromatidis

    Molecular and Cellular Biochemistry (2022)

  • Cerebrospinal beta-amyloid peptides(1-40) and (1-42) in severe preeclampsia and HELLP syndrome – a pilot study

    • Wolfgang Lederer
    • Helene Schaffenrath
    • Christian Humpel

    Scientific Reports (2020)

  • An Insight into the Angiogenic and Lymphatic Interplay in Pre-eclampsia Comorbid with HIV Infection

    • Zamahlabangane Mtshali
    • Jagidesa Moodley
    • Thajasvarie Naicker

    Current Hypertension Reports (2020)

  • Galectin-1 as a novel risk factor for both gestational hypertension and preeclampsia, specifially its expression at a low level in the second trimester and a high level after onset

    • Chikako Hirashima
    • Akihide Ohkuchi
    • Shigeki Matsubara

    Hypertension Research (2018)

  • Prediction and prevention of hypertensive disorders of pregnancy

    • Akihide Ohkuchi
    • Chikako Hirashima
    • Shigeki Matsubara

    Hypertension Research (2017)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information
  • Open Access Fees and Funding
  • Guide to Authors
  • About the Editors
  • Message from Editors
  • Call for Paper
  • Contact
  • About the Partner
  • For Advertisers
  • Subscribe
  • Showcase of Graphical Abstracts on Hypertension Research

Publish with us

  • For Authors & Referees
  • Language editing services
  • Open access funding
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Hypertension Research (Hypertens Res)

ISSN 1348-4214 (online)

ISSN 0916-9636 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited